Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis
Inventors
Cohen, Daniel • Chumakov, Ilya • Nabirochkin, Serguei • Guerassimenko, Oxana • Graudens, Esther
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11291670-B2
Publication Date
2022-04-05
Expiration Date
Abstract
The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that modulate angiogenesis for treating said disease.
Core Innovation
The disclosure relates to treating Alzheimer's disease in a subject suffering from Alzheimer's disease by chronic administration of baclofen, a salt of baclofen, or a sustained release formulation of baclofen or a baclofen salt, where baclofen is chronically administered orally at a dose of 0.4 mg to 40 mg per day. The disclosure further includes retardation or reduction of symptoms of Alzheimer's disease using the same baclofen-based chronic oral regimen.
The disclosure also provides protection of endothelial or neuronal cells against the toxicity of Abeta peptide in a subject having Alzheimer's disease, by chronically and orally administering baclofen or terbinafine, or salts or sustained release formulations, at a dose of 0.4 mg to 40 mg per day. The described protection is directed to toxicity of Abeta peptide in a subject context of Alzheimer's disease.
The disclosure further characterizes combination regimens in which baclofen or terbinafine are administered together with one or more additional specified compounds, with allowances for salts and sustained release formulations. Representative combinations include baclofen with levosimendan, sulfisoxazole, phenformin, or clopidogrel, and baclofen/terbinafine-based protective and therapeutic approaches are associated with changes in endothelial cell and neuronal cell outcomes in the presence of Abeta peptide toxicity.
Claims Coverage
The independent claims cover three treatment-oriented features: treating Alzheimer's disease, retardation or reduction of symptoms, and protection of endothelial or neuronal cells against Abeta peptide toxicity. The claim set centers on chronic oral baclofen or terbinafine regimens, salts and sustained release formulations, a defined daily dose range, and optional co-administration with specified additional compounds.
Chronic oral baclofen-based treatment of Alzheimer's disease
Chronic administration to a subject suffering from Alzheimer's disease of an effective amount of baclofen, a salt of baclofen, or a sustained release formulation of baclofen or the baclofen salt, wherein baclofen is chronically administered orally at a dose of 0.4 mg to 40 mg per day.
Chronic oral baclofen or terbinafine protection against Abeta peptide toxicity
Chronic administration to a subject having Alzheimer's disease of baclofen or terbinafine, or salts or sustained release formulations thereof, wherein the baclofen or terbinafine is chronically administered orally at a dose of 0.4 mg to 40 mg per day to protect endothelial or neuronal cells against the toxicity of Abeta peptide.
Chronic oral baclofen-based retardation or reduction of symptoms
Chronic administration to a subject suffering from Alzheimer's disease of an effective amount of baclofen, a salt of baclofen, or a sustained release formulation of baclofen or the baclofen salt, wherein baclofen is chronically administered orally at a dose of 0.4 mg to 40 mg per day for retardation or reduction of symptoms of Alzheimer's disease.
The claim coverage centers on chronic oral administration of baclofen, and in the protection claim also terbinafine, within 0.4 mg to 40 mg per day, including salts and sustained release formulations, for treatment of Alzheimer's disease, symptom reduction, or protection against Abeta peptide toxicity.
Stated Advantages
Protecting endothelial or neuronal cells against the toxicity of Abeta peptide in a subject having Alzheimer's disease.
Treating Alzheimer's disease in a subject suffering from Alzheimer's disease.
Retardation or reduction of symptoms of Alzheimer's disease.
Documented Applications
Protecting endothelial or neuronal cells against the toxicity of Abeta peptide in a subject having Alzheimer's disease.
Treating Alzheimer's disease in a subject suffering from Alzheimer's disease.
Retardation or reduction of symptoms of Alzheimer's disease in a subject suffering from Alzheimer's disease.
Interested in licensing this patent?